Skip to main content
Equibles
GTHP logo

GTHP · Guided Therapeutics Inc · Metrics

Track GTHP — free

Use GTHP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GTHP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.19 +0.03 (+18.75%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The factors below raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.”
View the 10-Q filed Aug 13, 2026
Market Cap
$18.34M
Shares
96.54M
Volume · Oct 20 154.21K Avg daily vol (3M) 36.07K

GTHP metrics

69 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.19
Market cap
$18.34M

Price action

20 metrics
Price change (1W)
+0.0%
Price change (30D)
-0.1%
Price change (3M)
-29.9%
Price change (6M)
-5.0%
Price change (YTD)
-64.8%
Price change (1Y)
-24.0%
Trailing year
Price change (5Y)
-66.3%
52-week high
$0.54
52-week low
$0.16
Change from 52-week high
-64.8%
Change from 52-week low
+18.8%
Annualized volatility
196.6%
Annualized volatility (3M)
—
Beta
-1.9
RSI (14D)
46.0
Price vs SMA 50
-19.6%
Price vs SMA 200
-30.3%
Avg volume (3M)
36,068
Relative volume
4.3
Average dollar volume
$7,051

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
96.54M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
28.3×
reciprocal yield 3.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
28.2×
reciprocal yield 3.5%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-16.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
189.2×
reciprocal yield 0.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
75.7%
Operating margin
-303.8%
Trailing 12 months
Net margin
-471.2%
Gross profit (TTM)
$492,000
Operating profit (TTM)
−$1.98M
Net income (TTM)
−$3.06M
Trailing 12 months
Diluted EPS (TTM)
$-0.04
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.01
Gross profit per diluted share (TTM)
$0.01
Operating profit per diluted share (TTM)
$-0.02
EBITDA per diluted share (TTM)
$-86.37
Net income per diluted share (TTM)
$-0.04
Operating cash flow per diluted share (TTM)
$-0.02
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
$0.00
Book value per share
$-0.07

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$650,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+22.4%
Year over year · more shares
Revenue CAGR (3Y)
+289.3%
Revenue CAGR (5Y)
+49.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-256.3%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$1.05M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-3.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$41,000
Latest balance sheet
Cash & equivalents
$12,000
Total assets
$1.20M
Total debt
$53,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.50M
Capital expenditures (TTM)
$0
R&D (TTM)
$341,000
SG&A (TTM)
—
Stock compensation (TTM)
$126,000
R&D / revenue
52.5%
Stock compensation / revenue
19.4%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
28 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 924515 CUSIP 40171F501 Visit website Investor relations